Koch Disruptive Technologies to Lead $150 Million Investment of INSIGHTEC

PR71564

WICHITA, Kansas and HAIFA, Israel, Dec. 14, 2017 /PRNewswire=KYODO JBN/ --

- The medical device company is transforming neurological treatments through

its non-invasive focused ultrasound applications

Koch Disruptive Technologies, a subsidiary of Koch Industries focused on

finding and funding innovative and emerging companies, is the lead investor in

a $150 million Series E funding round for INSIGHTEC, a commercial-stage medical

device company revolutionizing surgery with MRI-guided focused ultrasound.

     (Logo: http://mma.prnewswire.com/media/619739/INSIGHTEC_Logo.jpg )

     (Logo: http://mma.prnewswire.com/media/619740/Koch_Industries_Logo.jpg )

The investment, announced Thursday, will allow the company to further

commercialize its approved indications, as well as continue research in areas

such as Parkinson's disease, Alzheimer's disease and brain tumors, using the

company's breakthrough technology to deliver treatment in a non-invasive way.

It is also the first investment for Koch Disruptive Technologies since the

business group, led by KDT President Chase Koch, commenced operations in

November.

"This investment aligns well with the founding principles of both Koch

Disruptive Technologies and Koch Industries," said Koch. "With a track record

of driving innovation and improving patient outcomes, INSIGHTEC has itself

invested and expanded its capabilities to advance surgical medicine to improve

the health and quality of life of millions of patients."

"Hospitals around the world are increasingly pursuing incisionless treatment

options for their patients using our focused ultrasound therapy," said Maurice

R. Ferré, MD, INSIGHTEC's CEO and Chairman of the Board, who has led multiple

transformative medical technology companies throughout his career. "This

investment round elevates INSIGHTEC into a new strategic position within the

health care industry."

INSIGHTEC's Exablate Neuro is the first focused ultrasound device approved by

the FDA to treat essential tremor that has not responded to medication and

recently received the Best Medical Technology award by Prix Galien. The company

surpassed the 1,000th patient milestone earlier this year, as essential tremor

patients are routinely being treated with focused ultrasound at 40 medical

centers around the world.

With more than 20,000 procedures for a range of clinical applications already

performed with its technology, this investment will allow INSIGHTEC to drive

further uses of MR-guided ultrasound to treat Parkinson's disease, prostate

cancer, liver cancer and pancreatic cancer. Clinical research with the

company's technology has already successfully disrupted the blood-brain

barrier, which holds the potential for targeted drug delivery to treat

Alzheimer's disease and brain tumors.

"Transformative ideas know no borders and can come from anyone, anywhere," said

Steve Feilmeier, Executive President and CFO, Koch Industries, Inc. "We are

well-positioned to harness these breakthroughs happening all over the globe and

to also support the next generation of promising entrepreneurs."

Jefferies LLC, the global investment banking firm, advised INSIGHTEC for the

investment round. Existing investors in INSIGHTEC include Elbit Imaging, York

Capital, Focus Holdings, GE Healthcare, GEOC, and Meditech Advisors. INSIGHTEC

is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Tokyo and

Shanghai.

About Koch Industries

Based in Wichita, Kansas, Koch Industries, Inc. is one of the largest private

companies in America with estimated annual revenues as high as $100 billion,

according to Forbes. It owns a diverse group of companies involved in refining,

chemicals, and biofuels; forest and consumer products; fertilizers; polymers

and fibers; process and pollution control equipment and technologies;

electronics; information systems; commodity trading; minerals; energy; glass;

ranching; and investments. Since 2003, Koch companies have invested more than

$80 billion in acquisitions and other capital expenditures. With a presence in

about 60 countries, Koch companies employ more than 120,000 people worldwide,

with about 70,000 of those in the United States. From January 2009 to present,

Koch companies have earned more than 1,200 awards for safety, environmental

excellence, community stewardship, innovation, and customer service. For more

news and stories, visit http://www.kochnews.com.

About Koch Disruptive Technologies

Founded in November 2017 upon the spirit of transformation, Koch Disruptive

Technologies originates and invests in promising entrepreneurs and technologies

across industries to improve Koch's existing businesses and create new

opportunities. Learn more:

http://news.kochind.com/news/2017/koch-disruptive-technologies-ready-to-transform

About INSIGHTEC

INSIGHTEC is the world leader and innovator of MR-guided Focused Ultrasound.

The company's non-invasive therapy platforms, Exablate and Exablate Neuro, are

proven technology based on sound clinical evidence for treating essential

tremor, painful bone metastases and uterine fibroids. The company is dedicated

to improving patient lives by collaborating with physicians, medical

institutions, academic researchers and regulatory bodies around the world.

For more information, please visit: http://www.insightec.com

Media Contacts:

Michelle Barry

Red Lorry Yellow Lorry for INSIGHTEC

insightec@rlyl.com

(857)217-2886

David Dziok

Koch Industries

david.dziok@kochps.com

(202)879-8575

Source: INSIGHTEC and Koch Disruptive Technologies